V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310008065 | 310005204 | 1.85 | null | Curative (C) | 2017-04-24 | 2017-04-24 | Capecitabine + Oxaliplatin 21day | 2 | N | 310023903 | VEMURAFENIB |
| 310008066 | 310005205 | 0 | 58 | Curative (C) | 2014-10-01 | 2014-10-08 | ICE | N | N | 310023920 | DOXORUBICIN |
| 310008067 | 310008283 | 1.77 | null | Disease modification (D) | 2016-10-03 | 2016-10-27 | Capecitabine | 02 | null | 310023925 | NIVOLUMAB |
| 310008068 | 310008283 | 1.68 | 64.9 | Palliative (P) | 2016-02-26 | 2016-02-28 | OCTOPUS Trial | N | N | 310023925 | CISPLATIN + ETOPOSIDE |
| 310008069 | 310008283 | 1.83 | 64.5 | Curative (C) | 2016-04-29 | 2016-05-13 | CISPLATIN + FLUOROURACIL | Y | N | 310023925 | TOPOTECAN |
| 310008070 | 310005206 | 1.74 | null | null | 2017-04-09 | 2017-04-09 | Methotrexate Intermed dose (1g/m2) | 02 | N | 310023964 | POUT TRIAL |
| 310008071 | 310005206 | 1.56 | 74.4 | Curative (C) | 2017-12-20 | 2017-12-23 | ECarboX | N | N | 310023964 | MITOMYCIN |
| 310008072 | 310009918 | 1.59 | 67.7 | Palliative (P) | 2013-05-31 | 2013-06-01 | IDELALISIB | 02 | N | 310023985 | NIVOLUMAB |
| 310008073 | 310005207 | null | 80.6 | Neo-adjuvant (N) | null | 2018-04-11 | Vemurafenib | 02 | N | 310023990 | CARBO + FLUOROURACIL |
| 310008074 | 310005207 | 1.73 | null | Curative (C) | 2014-03-21 | 2014-04-25 | Methotrexate Intermed dose (1g/m2) | N | N | 310023990 | TRASTUZUMAB |
| 310008075 | 310005210 | 1.8 | 114.8 | Neo-adjuvant (N) | null | 2016-04-08 | Temozolomide 200mg/m2 | 02 | N | 310023999 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 310008076 | 310005212 | 1.53 | 63 | Palliative (P) | 2014-06-06 | 2014-06-07 | Capecitabine | 2 | N | 310024014 | VEDEX |
| 310008077 | 310005212 | 1.55 | 70 | Palliative (P) | 2016-11-05 | 2017-02-14 | Eribulin | N | N | 310024014 | EOX |
| 310008078 | 310005213 | 1.72 | null | Palliative (P) | null | 2016-03-23 | CODOX M | N | N | 310024026 | TRIPLE INTRATHECAL |
| 310008079 | 310008288 | null | 65.1 | Curative (C) | 2016-06-21 | 2016-06-23 | Temozolomide 200mg/m2 | N | N | 310024046 | TEMOZOLOMIDE |
| 310008080 | 310005215 | null | 65.9 | Palliative (P) | null | 2015-05-08 | ALL Int GdeC D Int PhIV recon Pasp | N | N | 310024076 | TEMOZOLOMIDE |
| 310008081 | 310005217 | 1.85 | 0 | Palliative (P) | 2016-10-27 | 2016-11-16 | EOX | 2 | N | 310024082 | PEG INTERFERON |
| 310008082 | 310005217 | 1.6 | 92.399 | null | 2014-10-30 | 2014-12-06 | MELPHALAN | N | null | 310024082 | R IVAC |
| 310008083 | 310005218 | null | null | Palliative (P) | 2016-10-16 | 2016-10-17 | PEG INTERFERON | 2 | N | 310024105 | FLUOROURACIL + MITOMYCIN + RT |
| 310008084 | 310005219 | 1.78 | 63 | Palliative (P) | 2017-01-25 | 2017-02-06 | BCG Intravesical | null | null | 310024123 | LENALIDOMIDE |
| 310008085 | 310005220 | 1.79 | 87.2 | Palliative (P) | 2015-06-09 | 2015-06-09 | OCTOPUS Trial | null | null | 310024128 | CAV |
| 310008086 | 310005221 | 1.87 | 108 | Palliative (P) | 2016-04-10 | 2016-04-10 | R GCVP | N | N | 310024138 | BEP |
| 310008088 | 310005224 | 1.66 | 50 | Palliative (P) | 2017-03-20 | 2017-03-28 | ICON8 TRIAL | N | N | 310024150 | UKALL2014 |
| 310008089 | 310005224 | 1.75 | 63 | Palliative (P) | 2014-07-01 | 2014-12-29 | Oxaliplatin + Modified de Gramont | N | N | 310024150 | BEP |
| 310008090 | 310005224 | 0 | 64 | Palliative (P) | 2014-10-02 | 2014-10-21 | Pazopanib | Y | N | 310024150 | CABAZITAXEL |
| 310008091 | 310008293 | 1.8 | 90.5 | Curative (C) | 2014-04-06 | 2014-05-19 | EOX | N | null | 310024177 | DACARBAZINE |
| 310008092 | 310008293 | 1.73 | null | Adjuvant (A) | 2014-07-18 | 2014-12-01 | Epirubicin | 02 | N | 310024177 | CAPECITABINE + CARBOPLATIN |
| 310008093 | 310008293 | null | 57.25 | null | null | 2015-06-05 | Cytarabine intrathecal | N | N | 310024177 | INTERFERON |
| 310008094 | 310011744 | 1.78 | 68.8 | Disease modification (D) | 2015-12-03 | 2015-12-03 | BLEOMYCIN | N | N | 310024235 | ECX |
| 310008095 | 310005226 | 1.62 | 88.5 | Adjuvant (A) | 2017-12-28 | 2018-01-03 | PMitCEBO | 02 | N | 310024239 | DACARBAZINE |
| 310008096 | 310005228 | 1.57 | 85.6 | Disease modification (D) | 2014-06-10 | 2014-06-10 | MERCAPTOPURINE + METHOTREXATE | N | N | 310024239 | PEG INTERFERON |
| 310008097 | 310005228 | 1.83 | 73 | Palliative (P) | 2014-03-12 | 2014-03-12 | EOX | 02 | N | 310024239 | EP |
| 310008098 | 310005230 | 1.74 | 80.7 | Curative (C) | 2016-06-04 | 2016-09-02 | Arsenic Trioxide (consolidation) | 02 | N | 310024278 | ETOPOSIDE + MELPHALAN |
| 310008099 | 310010805 | 0 | 66.8 | Palliative (P) | 2013-07-19 | 2013-07-19 | POUT TRIAL | N | N | 310024290 | BENDAMUSTINE |
| 310008100 | 310005232 | 1.84 | 71.1 | Palliative (P) | 2013-07-03 | 2014-03-31 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 310024315 | CAV |
| 310008101 | 310005232 | null | 0 | Palliative (P) | 2015-11-09 | 2016-04-11 | Cytarabine intrathecal | 02 | N | 310024315 | SUNITINIB |
| 310008102 | 310008298 | 1.59 | 118 | Palliative (P) | 2013-11-03 | 2013-11-03 | Topotecan IV 7 day | 2 | N | 310024324 | ICON8B TRIAL |
| 310008103 | 310005236 | null | 74.5 | Palliative (P) | null | 2014-02-21 | PCV | N | N | 310024355 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 310008104 | 310005236 | 1.78 | 81 | Curative (C) | 2014-10-08 | 2015-01-01 | LENALIDOMIDE | N | null | 310024355 | VINBLASTINE |
| 310008105 | 310005237 | 1.59 | 73.7 | null | 2018-05-31 | 2018-06-01 | FLUOROURACIL + IRINOTECAN | N | N | 310024393 | OCTOPUS TRIAL |
| 310008106 | 310008300 | 0 | 72.05 | Curative (C) | 2013-08-24 | 2013-08-31 | DOXORUBICIN | N | N | 310024393 | RMS 2005 TRIAL |
| 310008107 | 310008300 | 1.6 | 88 | Palliative (P) | null | 2013-09-25 | EVEROLIMUS | N | N | 310024393 | OCTOPUS TRIAL |
| 310008108 | 310008300 | 1.65 | 14.9 | Palliative (P) | null | 2016-09-11 | ICE (no GCSF) | 02 | N | 310024393 | CARBOPLATIN + RT |
| 310008109 | 310011843 | null | 89.4 | Palliative (P) | 2016-12-24 | 2017-04-14 | Cyclophosphamide+Fludara+TBI Allo | N | N | 310024441 | ENZALUTAMIDE |
| 310008110 | 310005240 | null | null | Palliative (P) | 2016-02-03 | 2016-03-05 | Dacarbazine | null | N | 310024441 | OXALIPLATIN + MDG |
| 310008111 | 310005242 | null | null | Curative (C) | 2014-09-12 | 2014-09-12 | Gemcitabine + Oxaliplatin | 02 | null | 310024459 | ECX |
| 310008112 | 310005242 | 1.81 | 55.8 | Palliative (P) | 2014-01-27 | 2014-12-09 | Topotecan (intravenous) | N | N | 310024459 | BEVACIZUMAB + OXALIPLATIN + MdG |
| 310008113 | 310005242 | null | 75 | Not known (9) | 2016-04-03 | 2016-05-03 | Cytarabine intrathecal | 2 | N | 310024459 | DACARBAZINE |
| 310008114 | 310005242 | 1.61 | 72 | null | 2014-06-24 | 2014-07-01 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 310024459 | VEMURAFENIB |
| 310008115 | 310005244 | 1.55 | null | Curative (C) | 2014-11-02 | 2014-11-30 | STS Rhabdomyosarcoma RMS 2005 IVA | 2 | N | 310024502 | ICON TRIAL |